Soft Tissue Sarcoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc, Lyvgen Biopharma Holdings Limited, Chipscre

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Soft Tissue Sarcoma pipeline constitutes 125+ key companies continuously working towards developing 130+ Soft Tissue Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Soft Tissue Sarcoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Soft Tissue Sarcoma Market.

The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Soft Tissue Sarcoma Pipeline Report: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Soft Tissue Sarcoma treatment therapies with a considerable amount of success over the years.
• Soft Tissue Sarcoma companies working in the treatment market are OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc, Lyvgen Biopharma Holdings Limited, Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, LLC, Philogen S.p.A., Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others, are developing therapies for the Soft Tissue Sarcoma treatment
• Emerging Soft Tissue Sarcoma therapies in the different phases of clinical trials are- OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, GPX-150, LTX-315, Lurbinectedin, and others are expected to have a significant impact on the Soft Tissue Sarcoma market in the coming years.
• In October 2022, LIXTE Biotechnology Holdings, Inc. revealed that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) granted authorization for a Phase 1b/randomized Phase 2 study involving LB-100, the company's primary clinical compound. The study is designed to evaluate LB-100 in combination with doxorubicin compared to the use of doxorubicin alone, which is the established global standard for the initial treatment of advanced soft tissue sarcomas (ASTS).
• In September 2022, Immutep Limited has recently finalized a Material Transfer Agreement ("Agreement") with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. This agreement facilitates an investigator-initiated open-label Phase II clinical trial, aiming to assess Immutep's primary product candidate, efti, alongside pembrolizumab and radiotherapy in the neoadjuvant setting (before surgery). The trial targets up to 40 patients diagnosed with specific types of soft tissue sarcoma (STS).
• In September 2022, TRACON Pharmaceuticals, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded fast-track designation to facilitate the development of envafolimab (KN035). This designation aims to expedite the process for patients diagnosed with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have experienced progression following one or two prior lines of chemotherapy.
• In September 2022, Avacta Group plc disclosed that the US Food and Drug Administration (FDA) has bestowed Orphan Drug Designation (ODD) upon the company's primary pre|CISION drug candidate, AVA6000, intended for treating soft tissue sarcoma. AVA6000, a modified version of the generic chemotherapy drug doxorubicin, utilizes the pre|CISION technology to primarily activate within the tumor, with the goal of minimizing healthy tissue exposure. This modification aims to enhance the drug's safety, tolerability, and effectiveness.

Soft Tissue Sarcoma Overview
Soft tissue sarcoma (STS) refers to a diverse group of cancers that originate in the soft tissues of the body. These tissues encompass muscles, tendons, fat, blood vessels, nerves, and deep skin tissues.

Get a Free Sample PDF Report to know more about Soft Tissue Sarcoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Soft Tissue Sarcoma Drugs Under Different Phases of Clinical Development Include:
• OTSA101-DTPA111In: OncoTherapy Science, Inc.
• FHD-609: Foghorn Therapeutics Inc.
• CFT8634: C4 Therapeutics, Inc
• LVGN6051 + Anlotinib: Lyvgen Biopharma Holdings Limited
• Chiauranib: Chipscreen Biosciences, Ltd.
• MNPR 201: Monopar Therapeutics
• AL3818: Advenchen Laboratories, LLC
• Fibronum + Doxorubicin: Philogen S.p.A.
• GPX-150: Monopar Therapeutics
• LTX-315: Lytix Biopharma
• Lurbinectedin: Jazz Pharmaceuticals

Soft Tissue Sarcoma Route of Administration
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Soft Tissue Sarcoma Molecule Type
Soft Tissue Sarcoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Soft Tissue Sarcoma Pipeline Therapeutics Assessment
• Soft Tissue Sarcoma Assessment by Product Type
• Soft Tissue Sarcoma By Stage and Product Type
• Soft Tissue Sarcoma Assessment by Route of Administration
• Soft Tissue Sarcoma By Stage and Route of Administration
• Soft Tissue Sarcoma Assessment by Molecule Type
• Soft Tissue Sarcoma by Stage and Molecule Type

DelveInsight's Soft Tissue Sarcoma Report covers around 130+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Soft Tissue Sarcoma product details are provided in the report. Download the Soft Tissue Sarcoma pipeline report to learn more about the emerging Soft Tissue Sarcoma therapies at:
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Soft Tissue Sarcoma Therapeutics Market include:
Key companies developing therapies for Soft Tissue Sarcoma are - AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, and others.

Soft Tissue Sarcoma Pipeline Analysis:
The Soft Tissue Sarcoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
• Soft Tissue Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Soft Tissue Sarcoma drugs and therapies-
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Soft Tissue Sarcoma Pipeline Market Drivers
• Increase in Cancer Cases, rising Involvement of Clinical Trials are some of the important factors that are fueling the Soft Tissue Sarcoma Market.

Soft Tissue Sarcoma Pipeline Market Barriers
• However, side-Effects of Soft Tissue Sarcoma Drugs, increasing Cost of Treatments and other factors are creating obstacles in the Soft Tissue Sarcoma Market growth.

Scope of Soft Tissue Sarcoma Pipeline Drug Insight
• Coverage: Global
• Key Soft Tissue Sarcoma Companies: OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc, Lyvgen Biopharma Holdings Limited, Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, LLC, Philogen S.p.A., Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others
• Key Soft Tissue Sarcoma Therapies: OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, GPX-150, LTX-315, Lurbinectedin, and others
• Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies
• Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers

Request for Sample PDF Report for Soft Tissue Sarcoma Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Soft Tissue Sarcoma Report Introduction
2. Soft Tissue Sarcoma Executive Summary
3. Soft Tissue Sarcoma Overview
4. Soft Tissue Sarcoma- Analytical Perspective In-depth Commercial Assessment
5. Soft Tissue Sarcoma Pipeline Therapeutics
6. Soft Tissue Sarcoma Late Stage Products (Phase II/III)
7. Soft Tissue Sarcoma Mid Stage Products (Phase II)
8. Soft Tissue Sarcoma Early Stage Products (Phase I)
9. Soft Tissue Sarcoma Preclinical Stage Products
10. Soft Tissue Sarcoma Therapeutics Assessment
11. Soft Tissue Sarcoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Soft Tissue Sarcoma Key Companies
14. Soft Tissue Sarcoma Key Products
15. Soft Tissue Sarcoma Unmet Needs
16 . Soft Tissue Sarcoma Market Drivers and Barriers
17. Soft Tissue Sarcoma Future Perspectives and Conclusion
18. Soft Tissue Sarcoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Soft Tissue Sarcoma Market https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Soft Tissue Sarcoma Epidemiology https://www.delveinsight.com/report-store/soft-tissue-sarcoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Soft Tissue Sarcoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.